Bio-Rad Laboratories, Inc. (NYSE: BIO) reported Q1 EPS of $1.16, $0.16 worse than the analyst estimate of $1.32. Revenue for the quarter came in at $485.1 million versus the consensus estimate of $482.11 million.

Earnings